Screening, Imaging, and Image-Guided Biopsy Techniques for Breast Cancer

Breast Imaging, Department of Radiology, Ochsner Health System, 1516 Jefferson Highway, New Orleans, LA 70121, USA. Electronic address: .
Surgical Clinics of North America (Impact Factor: 1.88). 04/2013; 93(2):309-27. DOI: 10.1016/j.suc.2013.01.004
Source: PubMed


Mammography remains the primary modality for breast cancer diagnosis. Other imaging studies, most commonly ultrasonography and magnetic resonance imaging, are also used to characterize breast lesions, stage breast cancer, and aid in surgical planning. Although mammography is the only screening examination demonstrated to decrease breast cancer mortality in the general population, other imaging studies have been shown to be beneficial for screening high-risk patients. In the future, new technologies may also improve the sensitivity and specificity of breast cancer screening and detection.

22 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evidence-based screening guidelines issued by national organizations sometimes contradict each other, leading to confusion among health care providers and the women they care for. This article summarizes the most recent guidelines for breast and cervical cancer screening and notes where they concur and where they diverge.
    Nursing for Women s Health 08/2013; 17(4):331-5. DOI:10.1111/1751-486X.12052
  • [Show abstract] [Hide abstract]
    ABSTRACT: The tumor microenvironment plays an important role in breast carcinogenesis. Milk acts as an important microenvironment of breast cancer, but its role in breast carcinogenesis is largely unknown. Milk stasis may exist in the breast for a number of years after breastfeeding. In the present study, we reported the first microRNA (miRNA) profiling of milk from patients with milk stasis. We identified 266 known miRNAs and 271 novel miRNAs in 10 milk stasis only samples, 271 known miRNAs and 140 novel miRNAs in 10 milk stasis plus breast neoplasm samples by deep sequencing. miRNA profiles were different between the two groups. Furthermore, nine tumor suppressor miRNAs such as miR-29a, miR-146 and miR-223 were significantly downregulated, while seven oncogenic miRNAs such as miR-451, miR-486, miR-107, miR-92 and miR-10 were significantly upregulated in the milk of milk stasis plus neoplasm patients. Three of the identified miRNAs (miR-140, miR-21 and let-7a) were selected using real-time PCR, confirming that these miRNAs were highly expressed. The results also showed that the three miRNAs detected were more abundant in the milk than in the blood. In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
    International Journal of Molecular Medicine 02/2014; 33(5). DOI:10.3892/ijmm.2014.1677 · 2.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a group of diseases that can be managed if diagnosed early. In the past few decades, we have made considerable advances in diagnosis, and opened new avenues for early identifi cation of cancer. Even with tremendous eff orts, it appears that we have a long way to go in terms of making a full-proof diagnosis at the early stage of cancer development. Th e key hurdle in cancer diagnosis is the availability of cancer cells and markers in body fl uids. In the contemporary era of new materials in pace with advance technology, we can look forward for better diagnosis. Treatment is another revolting aspect of cancer. Present diagnostics can pick up cancer cells aft er plentiful development; by this time metastasis might have already been started. Decimation of cancer stem cells deep into tissue provides a safe niche to hide and facilitate cancer cells to proliferate to new tumors. Metastasis enables a good amount of cancerous cells to remain away from drugs. Although the search for new anticancer drugs is always in demand, at the same time, it is necessary to fi nd out the mode of delivering the drug to every single niche which can hide and nourish the cancer cells. In the present age of treatment, we have to look forward for using new methods and technology like nanoparticle drug delivery system to overcome this obstacle. Th ere is a lot of scope to ameliorate the existing technology with advance materials for making substantial progress in cancer diagnosis and treatment.
    Advanced Healthcare Materials, 05/2014: pages 37-47; , ISBN: 9781118773598
Show more

Similar Publications